This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer
by Zacks Equity Research
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.
Regeneron, Lilly Get New COVID Drug Deals From Government
by Zacks Equity Research
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
by Zacks Equity Research
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
by Zacks Equity Research
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
Will Regeneron's (REGN) Antibody Cocktail Fuel Further Growth?
by Zacks Equity Research
Regeneron's (REGN) performance in the year has gained from higher demand for its antibody cocktail - REGEN-COV.
Roche's (RHHBY) Sparks Set to Develop Gene Therapy for HD
by Zacks Equity Research
Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
by Zacks Equity Research
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.
by Zacks Equity Research
Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
by Zacks Equity Research
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.
Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK
by Zacks Equity Research
Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
by Zacks Equity Research
Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.